Literature DB >> 33682858

Stereotaxic Intracranial Delivery of Chemicals, Proteins or Viral Vectors to Study Parkinson's Disease.

Natalie Landeck1, Melissa Conti Mazza2, Megan Duffy2, Christopher Bishop3, Caryl E Sortwell4, Mark R Cookson2.   

Abstract

Parkinson's disease (PD) is a progressive disorder traditionally defined by resting tremor and akinesia, primarily due to loss of dopaminergic neurons in the substantia nigra. Affected brain areas display intraneuronal fibrillar inclusions consisting mainly of alpha-synuclein (asyn) proteins. No animal model thus far has recapitulated all characteristics of this disease. Here, we describe the use of stereotaxic injection to deliver chemicals, proteins, or viral vectors intracranially in order to mimic various aspects of PD. These methods are well-established and widely used throughout the PD field. Stereotaxic injections are incredibly flexible; they can be adjusted in concentration, age of animal used for injection, brain area targeted and in animal species used. Combinations of substances allow for rapid variations to assess treatments or alter severity of the pathology or behavioral deficits. By injecting toxins into the brain, we can mimic inflammation and/or a severe loss of dopaminergic neurons resulting in substantial motor phenotypes. Viral vectors can be used to transduce cells to mimic genetic or mechanistic aspects. Preformed fibrillar asyn injections best recapitulate the progressive phenotype over an extended period of time. Once these methods are established, it can be economical to generate a new model compared to creating a new transgenic line. However, this method is labor intensive as it requires 30 minutes to four hours per animal depending on the model used. Each animal will have a slightly different targeting and therefore create a diverse cohort which on one hand can be challenging to interpret results from; on the other hand, help mimic a more realistic diversity found in patients. Mistargeted animals can be identified using behavioral or imaging readouts, or only after being sacrificed leading to smallercohort size after the study has already been concluded. Overall, this method is a rudimentary but effective way to assess a diverse set of PD aspects.

Entities:  

Mesh:

Year:  2021        PMID: 33682858      PMCID: PMC8981414          DOI: 10.3791/62128

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  28 in total

1.  Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice.

Authors:  Kelvin C Luk; Victoria Kehm; Jenna Carroll; Bin Zhang; Patrick O'Brien; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2012-11-16       Impact factor: 47.728

Review 2.  MPTP mouse models of Parkinson's disease: an update.

Authors:  Gloria E Meredith; David J Rademacher
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

Review 3.  Pesticides exposure as etiological factors of Parkinson's disease and other neurodegenerative diseases--a mechanistic approach.

Authors:  Maria Teresa Baltazar; Ricardo Jorge Dinis-Oliveira; Maria de Lourdes Bastos; Aristidis M Tsatsakis; José Alberto Duarte; Félix Carvalho
Journal:  Toxicol Lett       Date:  2014-02-03       Impact factor: 4.372

4.  Toxic effects of human and rodent variants of alpha-synuclein in vivo.

Authors:  Natalie Landeck; Kerstin Buck; Deniz Kirik
Journal:  Eur J Neurosci       Date:  2017-01-11       Impact factor: 3.386

5.  Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry.

Authors:  H Braak; D Sandmann-Keil; W Gai; E Braak
Journal:  Neurosci Lett       Date:  1999-04-09       Impact factor: 3.046

6.  Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease.

Authors:  Tomas Björklund; Thomas Carlsson; Erik Ahlm Cederfjäll; Manolo Carta; Deniz Kirik
Journal:  Brain       Date:  2010-02-02       Impact factor: 13.501

7.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

8.  Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease.

Authors:  Michael X Henderson; Dustin J Covell; Charlotte Hiu-Yan Chung; Rose M Pitkin; Raizel M Sandler; Samantha C Decker; Dawn M Riddle; Bin Zhang; Ronald J Gathagan; Michael J James; John Q Trojanowski; Kurt R Brunden; Virginia M Y Lee; Kelvin C Luk
Journal:  Neurobiol Dis       Date:  2019-12-16       Impact factor: 5.996

9.  Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice.

Authors:  Kelvin C Luk; Victoria M Kehm; Bin Zhang; Patrick O'Brien; John Q Trojanowski; Virginia M Y Lee
Journal:  J Exp Med       Date:  2012-04-16       Impact factor: 14.307

10.  Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents.

Authors:  Nicole K Polinski; Laura A Volpicelli-Daley; Caryl E Sortwell; Kelvin C Luk; Nunilo Cremades; Lindsey M Gottler; Jessica Froula; Megan F Duffy; Virginia M Y Lee; Terina N Martinez; Kuldip D Dave
Journal:  J Parkinsons Dis       Date:  2018       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.